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Effect of furosemide-induced hypokalemic metabolic alkalosis on renal
transport enzymes. Hypokalemic metabolic alkalosis is one of the most
common complications of chronic furosemide administration. In this
study we examined acid-base composition and ATPase enzyme activi-
ties in medullary thick ascending limb of Henle's loop (MTAL) and
collecting tubule (CCT and MCT) after seven days of chronic fu-
rosemide therapy. All of the studies were conducted in adrenal intact
(Al) rats or in adrenalectomized (ADX) glucocorticoid replete rats
replaced with a physiological dose of aldosterone (Aldo). Furosemide
(F) was administered to each rat by mini-osmotic pump. In the Al + F
group, plasma Aldo was high and obvious metabolic alkalosis occurred(HCO = 37 2 mEq/liter vs. 22 2mEq/liter in controls, P < 0.005);
activities of H-K-ATPase, H-ATPase, and Na-K-ATPase were in-
creased approximately twofold in both CCT and MCT. In the ADX +
F group (HCO = 28 2 mEq/liter, P < 0.05 from control), H-ATPase
activity was normal in CCT and it was slightly increased in MCT. CCT
and MCT H-K-ATPase activities were markedly increased (— twofold).
Na-K-ATPase actiyity was the same as control in CCT but it was
increased in MCT. In ADX + F + Vanadate (V) group which also had
normal Aldo levels, acid-base changes were modest (20 2 mEq/liter,
NS from control); in CCT and MCT H-K-ATPase and Na-K-ATPase
activities were markedly reduced, but H-ATPase activity in MCT was
increased. In all three experimental groups Na-K-ATPase activity in
MTAL was reduced fivefold. Hypokalemia developed in both intact and
ADX animals receiving furosemide. Thus, metabolic alkalosis in
chronic furosemide therapy is associated with stimulation of all three
collecting tubule ATPases. The high aldosterone level likely stimulates
the H-ATPase in both CCT and MCT; and in the former it also
stimulates Na-K-ATPase activity. The hypokalemia probably activates
H-K-ATPase in both CCT and MCT. Furosemide also appears to
directly stimulate H-ATPase activity in the MCT.
Hypokalemic metabolic alkalosis is one of the most common
complications of chronic furosemide (F) therapy [1—4]. The
underlying mechanisms for its generation and maintenance
involve aldosterone (Aldo) excess, hypokalemia, continued
increased sodium delivery to the distal nephron, volume con-
traction or chloride depletion [1]. Furosemide inhibits Na-K-
ATPase activity in the medullary thick ascending limb of
Henle's loop (MTAL) secondary to the fall in sodium entry at
the apical membrane [5]. The fall in sodium chloride reabsorp-
tion causes extracellular volume contraction which, in turn,
activates aldosterone secretion. Increased distal tubular fluid
flow, aldosterone, catecholamines, and antidiuretic hormone
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contribute to the increase in potassium secretion and are the
major mechanisms of kaliuresis [1—4].
The collecting tubule is the final site of urinary acidification
[6]. There, aldosterone and potassium influence the two renal
proton ATPases, the electrogenic H-ATPase and the electro-
neutral H-K-ATPase. Aldosterone stimulates collecting tubule
H-ATPase activity and potassium deficiency stimulates collect-
ing tubule H-K-ATPase activity [7—12]. Aldosterone stimulates
Na-K-ATPase activity in the cortical collecting tubule (CCT),
while hypokalemia stimulates Na-K-ATPase activity in the
medullary collecting tubule (MCT) [13—16].
We studied the effect of chronic furosemide administration on
acid-base balance and on isolated tubule enzyme activity in
rats. The results suggest that the interaction of aldosterone and
potassium alters enzyme activity in both CCT and MCT such
that both proton ATPases are stimulated, and thus maintain this
form of diuretic-induced metabolic alkalosis.
Methods
Preparation of animals
These studies were performed in both adrenal intact (Al) and
hormone-replete adrenalectomized (ADX) male albino Spra-
gue-Dawley rats (150 to 200 g). In order to maintain constant
drug delivery, furosemide was administered to each of the three
experimental groups (described below) using an osmotic mini-
pump (Aizet # 2002, Aiza Corp, Palo Alto, California, USA)
implanted subcutaneously in the intrascapular region of the
animal. Furosemide was dissolved in 0.9% sodium chloride at
alkaline pH (8.5 to 9.5, Tris buffer). The daily dose of fu-
rosemide administered was 3.5 mg, a dose known to produce
hypokalemic metabolic alkalosis in rats [17]. In the two groups,
animals received dexamethasone 1.4 g/100 g body wt/day and
aldosterone 1 sgIl00 g body wt/day (via a second osmotic
minipump) as maintenance glucocorticoid and mineralocorti-
coid replacement, respectively. Polyethylene glycol 400 was
used as the diluent. All animals had free access to the usual
laboratory diet and were given 0.3% NaC1 to drink ad libitum.
The influence of furosemide on acid-base composition and
H-ATPase, H-K-ATPase, Na-K-ATPase in MTAL and collect-
ing tubule (CCT and MCT) was investigated after seven days of
diuretic treatment. The animals were divided into four groups
(N = 6/group):
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Table 1. Effect of chronic furosemide (F) on metabolic parameters in adrenal intact (Al) and adrenalectomized (ADX) rats (N = 6/group)
Control Al + F ADX + F ADX + F + V
Pf( mEqi liter 4.1 0.2 2.4 02b 2.9 0.2"° 2.6 03b
ALDO ng/dl 34.5 2.5 97.7 6.9" 5.1 0.5 5.3 0.3
'Na mEq/liter 140 3 137 2 136 3 136 2
Pci ,nEq/liter 94 3 79 3° 81 2 83 2
Hct % 44.3 1.0 45.0 0.7 45.1 1.1 45.6 1.8
Ccr mI/mm 100 g body Wi 0.94 0.09 0.90 0.08 0.91 0.09 0.89 0.10
FENa % 1.5 0.2 5.1 08b 53 04b 5•5
FEK % 32,7 2 90.2 62b 87.4 7.8° 82.6 5.8"
FEE, % 2.7 0.2 7.9 0.4k' 8.3 0.6" 8.5 0.5"
Body wt g
Pre-treatment 149 3 148 2 149 2 147 3
Post-treatment 189 3 171 3 170 4° 168 3
Abbreviations are: P, plasma; Aldo, aldosterone; Hct, hematocrit; Car, creatinineclearance; FENa, fractional sodium excretion; FEK, fractional
potassium excretion; FEE,, fractional chloride excretion; V, chronic vanadate administration (see Methods for details).
P < 0.05 vs. control
b p < 0.01 vs. control
P < 0.05 vs. Al + F
' P < 0.01 vs. ADX + F and vs. ADX + F + V
Group 3 ADX + F
Group 4 ADX + F + sodium orthovanadate (V)
Sodium orthovanadate (V; 5 mg/kg, intraperitoneally), was
administered daily to rats for 10 days. This dose and duration of
V treatment have been previously demonstrated by us to
markedly inhibit H-K-ATPase activity in collecting tubule
segments and cause hypokalemic distal renal tubular acidosis
[18]. Sodium orthovanadate administration was begun for three
days before adrenalectomy and continued for the next seven
days. On the day before each experiment the rats were placed
in metabolic cages, and a twenty-four hour urine was collected
for measurement of sodium, potassium, chloride and creatinine
as previously described [18]. On the morning of the experiment,
the animals were anesthetized and a blood sample was obtained
from the abdominal aorta for measurement of arterial pH and
pCO2, creatinine, electrolytes, hematocrit, and aldosterone.
Plasma aldosterone concentration was determined by radio-
immunoassay method (COAT-A-COUNT© DPC Los Angeles,
California, USA).
Tubule microdissection and enzymatic measurements
The left renal artery was cannulated and the kidney was
perfused for 15 minutes in situ at a rate of 0.7 ml min' with a
balanced salt solution containing 400 U/mI collagenase, 4°C, pH
7.4. The kidneys were then cut along the cortico-papillary axis
and incubated in 3 ml of collagenase-albumin containing Hank's
solution at 35°C for 12 minutes. The tissues were continuously
bubbled with compressed air (3 psi). After incubation, the
pyramids were rinsed and immediately microdissected as pre-
viously described [19]. The tubule segments were identified
(MTAL, CCT and MCT) and tubule length was measured. To
remove most of the extracellular potassium, nephron segments
were incubated for 15 minutes at 37°C in K-free buffer [lii. The
nephron segments were then subjected to a two-step hypotonic-
hypothermic shock and ATPase activities were determined
using 'y 32P-labeled ATP (37°C, 15 mm, pH 7.4). H-ATPase,
H-K-ATPase, and Na-K-ATPase were measured radiochemi-
cally as previously described [18, 19].
Enzyme activity is expressed as pmol/mm tubule length/hr of
ATP hydrolyzed. All samples were run in triplicate or quadru-
plicate, and appropriate corrections were made for blanks and
the spontaneous hydrolysis of ATP.
Materials
All chemicals and reagents were obtained from Sigma Chem-
ical Co. (St. Louis, Missouri, USA) and were of highest purity.
Radiolabeled ATP was obtained from New England Nuclear
(Boston, Massachusetts, USA).
Statistics
The results are expressed as the mean SEM. Statistical
significance was assessed using the Student's i-test or analysis
of covariance, where appropriate, with P values of 0.05 or less
being significant.
Results
Metabolic data
Aldo levels in the Al + F group were markedly elevated (97.7
ng/di) (Table 1). In the ADX animals on replacement via
osmotic minipump, aldosterone levels averaged about 5 ng/dl
(that is, ADX + F and ADX + F + V groups), values
comparable to those measured in normal unstressed animals
[20]. The moderately high aldosterone level seen in control
animals (34,5 ng/dl) reflects the stress of surgery and anesthesia
[20]. Plasma potassium in the control group was 4.1 0.2
mEq/liter. Profound hypokalemia developed in all animals
receiving furosemide. Serum potassium averaged 2.5 mEq/liter
in the three groups (P < 0.01 vs. control). It should be noted
that hypokalemia occurred in both the ADX + F and ADX + F
+ V groups, groups in which aldosterone levels were physio-
logically normal owing to the miniosmotic pump infusion.
Plasma potassium in the Al + F group, the group having the
highest aldosterone level, was significantly lower than the
potassium noted in the ADX + F group (2.4 0.2 mEq/liter vs.
2.9 0.2 mEq/liter, respectively, P < 0.05). Plasma chloride
was decreased in the three experimental groups receiving
furosemide. As expected, the fractional excretion of sodium,
potassium and chloride was increased. Neither hematocrit nor
t
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Fig. 1. The effect of furosemide (F) on arterial blood pH and plasma
bicarbonate in adrenal intact (Al) and adrenalectomized (ADX) rats; N
= 6 in each group. Symbols are: (U) Al + F; () ADX + F; (J) ADX
+ F + V; () control. p < 0.05, *P < 0.005 vs. control animals; §P <
0.05 vs. Al + F; NS, not significant vs. control.
Fig. 2. The effect of furosemide (F) on H-ATPase activity in MTAL,
CCT, and MCT in adrenal intact (Al) and adrenalectomized (ADX)
rats; N = 6 in each group. Symbols are: (U) Al + F; () ADX + F; (El)
ADX + F + V; (0) control. P < 0.05, 1P < 0.005 vs. control animals;§P < 0.01 vs. A! + F (in MCT); NS = not significant vs. control.
As compared to control, animals in A! + F group (Fig. 1,
black bar), which had the highest aldosterone level and hy-
pokalemia, developed the most profound metabolic alkalosis(HCO = 36.6 1.2 mEq/liter vs. 22.4 2.1 mEqlliter,
respectively, P < 0.005). In the ADX + F group (Fig. 1, striped
bar), which had normal aldosterone levels and hypokalemia,
changes in acid-base status were significantly less severe than in
the Al + F group, but the bicarbonate was still significantly
greater than control (HCO 28.2 1.8 mEq/liter, P < 0.05
from control or from Al + F). On the other hand, in the ADX
+ F + V group (Fig. 1, stippled bar), which also had normal
aldosterone and hypokalemia only modest changes in acid-base
composition were observed (HCO =20.4 1.8 mEq/liter, NS
from control).
H-ATPase activity
In the Al + F group (Fig. 2, black bars) which had the highest
aldosterone levels, H-ATPase activity was markedly enhanced
in both CCT and MCT, but activity in MTAL remained un-
changed as compared to control. The percent increase in
H-ATPase activity in CCT and MCT averaged 74 7.6% and
104 8.4%, respectively (P < 0.005 from their controls). By
contrast, in the ADX + F group (Fig. 2, striped bars) which had
normal aldosterone levels, H-ATPase activity was similar to
control in both CCT and MTAL, while in MCT enzyme activity
was slightly but significantly increased (27 3.6% greater than
control, P < 0.05). In the ADX + F + V group (Fig. 2, stippled
bars), H-ATPase activity, again, was unchanged from control in
CCT; in MCT, enzyme activity was slightly increased (22
4.2% greater than control, P < 0.05). Of interest, H-ATPase
Fig. 3. The effect of furosemide (F) on H-K-A TPase activity in CCI
and MCT in adrenal intact (Al) and adrenalectoinized (ADX) rats; N =
6 in each group. Symbols are: (U) Al + F; () ADX + F; (0) ADX +
F + V; (0) control. P < 0.05, 1P < 0.005 vs. control animals.
activity in the MTAL of the vanadate-treated group was signif-
icantly increased (to 40 6.2% of control, P < 0.05).
H-K-A TPase activity
In the AT + F group (Fig. 3, black bars), H-K-ATPase
activity was markedly increased in CCT and MCT as compared
to control (Fig. 3, white bars). The percent increase in H-K-
ATPase activity in CCT and MCT averaged 101 12% and 131
21%, respectively (P < 0.01). In the ADX + F group (Fig. 3,
striped bars), the enzyme activities in CCT and MCT were also
very high and were similar to the Al + F group. H-K-ATPase
activities in CCT and MCT were enhanced by 92 7% and 113
12%, respectively (P < 0.01). In contradistinction, the ADX
+ F + V rats (Fig. 3, stippled bars) had a marked reduction in
H-K-ATPase activity in both CCT and MCT. The percent
decrease in the enzyme activity in CCT and MCT as compared
to control averaged 72 5%, 60 5%, respectively (P <
0.005). H-K-ATPase activity was very low in MTAL (data not
shown) in all experimental groups.
Na-K-A TPase activity
In the Al + F group (Fig. 4, black bars), Na-K-ATPase
activity in CCT and MCT was markedly stimulated as com-
pared to control (Fig. 4, white bars; to 128 21% and 140
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creatinine clearance was affected in the three experimental
groups as compared to control. Body weight at the beginning of
the study was identical in all four groups, however, at the end
of the study body weight in the three experimental groups was
significantly lower than in controls.
Alterations in acid-base composition
H
-A
TP
as
e 
a
ct
iv
ity
 
pm
ol
 m
rr
r'
 
hr
4 
H
-K
-A
TP
as
e 
a
ct
iv
ity
 
pm
ol
 m
rr
r' 
hr
4 
0 
8 
1*
 
I 
*
 
—
I 
*
 
C.
) 
*
 
—
I 
5000
4000
3000
2000
1000
0
1018 Eiam-Ong et a!: Renal ATPases in furosemide therapy
Fig. 4. The effect of furosemide (F) on Na-K-ATPase activity in
MTAL, CCT, and MCT in adrenal intact (Al) and adrenalectomized
(ADX) rats; N = 6 in each group, Symbols are: (U) A! + F; () ADX
+ F; (lii) ADX + F + V; (0) control. *<0.01, 1P < 0.005 vs. control
animals; §P < 0.05 vs. Al + F and vs. ADX + F; +P < 0.01 vs. Al +
F; NS = not significant vs. control.
21%, respectively, P < 0.01). On the other hand, Na-K-ATPase
activity in the ADX + F group (Fig. 4, striped bars) was not
significantly different from control in CCT. In MCT, Na-K-
ATPase activity was stimulated (to 127 20% of control, P <
0.01). In the ADX + F + V group (Fig. 4, stippled bars) there
was a marked reduction in Na-K-ATPase activity in both CCT
and MCT (to 46 4% and 44 6% of control, respectively, P
<0.01). In all the experimental groups there was approximately
an 80% reduction in Na-K-ATPase activity in MTAL. The
percent decrease in the enzyme activity averaged 80 5% in
the Al + F group, 81 5% in the ADX + F group, and 90 6%
in the ADX + F + V group (P < 0.005 vs. control). Na-K-
ATPase activity in MTAL, CCT and MCT in the vanadate-
treated group was significantly lower than that found in the
same nephron fragments of the Al + F and ADX + F groups.
Thus, in the Al + F group which had high aldosterone levels
and hypokalemia, severe metabolic alkalosis (HCO, 36.6
mEq/liter) occurred in association with stimulation of collecting
tubule H-ATPase, H-K-ATPase, and Na-K-ATPase activities.
In the ADX + F group, which had normal aldosterone levels
and hypokalemia, plasma bicarbonate was moderately higher
than control (that is, HCO of 28.2 mEq/liter vs. 22.4 mEqI
liter), and this was accompanied by increased H-K-ATPase
activity but normal H-ATPase activity. On the other hand, in
the ADX + F + V group which had normal aldosterone levels,
hypokalemia, and vanadate only modest changes in acid-base
composition were observed (HCO, 20.4 mEq/liter) in associ-
ation with markedly reduced collecting tubule H-K-ATPase and
Na-K-ATPase activities. This group also had increased MTAL
H-ATPase activity but its activity in the collecting tubule (CCT
and MCT) was unchanged.
Discussion
Hypokalemia is the most common complication of diuretic
use [2]. Furosemide can decrease the plasma potassium con-
centration of hypertensive patients who are not taking potas-
sium supplements by an average of 0.3 mmollliter in only one
week [21]. Studies demonstrate that the major mechanism of
the kaliuresis caused by loop diuretics is an increase in distal
potassium secretion [22]. Inhibition of potassium reabsorption
by the loop of Henle appears to play only a minor role in
potassium wastage [23]. Increased distal tubular fluid flow, and
increases in aldosterone, catecholamines, and antidiuretic hor-
mone further enhance distal potassium secretion.
Furosemide frequently causes metabolic alkalosis [1—4]. Dur-
ing initiation of therapy, the generation of metabolic alkalosis is
primarily caused by increased net acid excretion [24]. How-
ever, the maintenance of metabolic alkalosis is due to volume
contraction, hypokalemia, mineralocorticoid excess, and con-
tinued sodium delivery to the distal nephron [25].
The final regulation of urinary acidification occurs in the
collecting tubule [6]. According to current concepts collecting
tubule proton secretion is thought to be controlled by two
ATPases, the electrogenic H-ATPase and the electroneutral
H-K-ATPase [11, 12, 18, 26]. Previous studies have shown that
aldosterone stimulates collecting tubule H-ATPase activity
while plasma potassium controls H-K-ATPase activity [7—12].
When aldosterone rises and plasma potassium falls, both en-
zymes are stimulated and metabolic alkalosis occurs. When
these two enzymes change in different directions, however, the
effect on acid-base composition changes is modest (for exam-
ple, as might be seen with hypokalemia and decreased aldoste-
rone) [27].
The present studies were conducted to examine the effect of
furosemide on acid-base homeostasis and electrolyte composi-
tion and to correlate these findings with biochemical data on
renal transport in enzymes in rat microdissected MTAL, CCT
and MCT. The transport enzymes studied were Na-K-ATPase,
H-ATPase, and H-K-ATPase. The studies were performed in
both adrenal intact (Al) and hormone replete ADX animals. In
the ADX rats the animals were given a fixed physiologic dose of
aldosterone to control for the effects of the hormone on proton
secretion and potassium homeostasis. All ADX rats were
glucocorticoid replete. In the Al + F group, which had high
aldosterone levels and hypokalemia, profound metabolic alka-
losis occurred in association with stimulation of both collecting
tubule H-ATPase and H-K-ATPase. In the ADX + F group,
which had normal aldosterone levels and hypokalemia, plasma
bicarbonate increased moderately and only H-K-ATPase activ-
ity was substantially increased (in CCT and MCT). In this group
we also found that MCT H-ATPase activity was slightly in-
creased. In the ADX + F + V group, a group having normal
aldosterone levels and hypokalemia, plasma bicarbonate was
unchanged as compared to control. In the ADX + F + V
animals, collecting tubule H-K-ATPase activity was markedly
reduced; a slightly increased H-ATPase activity in MCT was
still observed, as noted in the ADX + F group. In a previous
study we showed that in adrenalectomized rats given a physi-
ologic dose aldosterone, MCT H-ATPase activity was identical
to control [27]. Therefore, the slightly increased MCT H-
ATPase activity observed in this study in both the ADX + F
and ADX + F + V groups is likely due to the stimulatory effect
of furosemide.
In the MTAL, H-ATPase were normal in the Al + F and the
ADX + F groups. In the ADX + F + V group, however,
H-ATPase activity of MTAL was increased while H-K-ATPase
activity was markedly decreased. This stimulatory effect of in
vivo vanadate on MTAL H-ATPase is similar to our previous
work showing stimulation of the enzyme by in vitro vanadate
[19].
Recent studies suggest that aldosterone plays the major role
in controlling Na-K-ATPase activity in CCT while hypokalemia
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exerts an aldosterone-independent stimulatory effect on the
enzyme in MCT [13—161. In agreement with these observations,
the Al + F group, which had very high aldosterone levels and
hypokalemia, had increased Na-K-ATPase activity in both CCT
and MCT. In the ADX + F group, animals which had normal
aldosterone levels and hypokalemia, Na-K-ATPase was in-
creased, but only in the MCT. Enzyme activity in CCT was
identical to control. Vanadate decreased Na-K-ATPase activity
in both CCT and MCT in the ADX + F + V group. The fall in
Na-K-ATPase was qualitatively, but not quantitatively, similar
to that seen when vanadate is administered alone to intact
animals [18]. Furosemide decreased MTAL Na-K-ATPase ac-
tivity in all three experimental groups. Vanadate administration
in the ADX + F + V group further depressed MTAL Na-K-
ATPase activity as compared to the values seen in the ADX +
F group.
The metabolic alkalosis of chronic furosemide administration
is associated with stimulation of collecting tubule ATPases. The
H-ATPase was stimulated by aldosterone while the H-K-
ATPase was activated by hypokalemia. In the CCT, Na-K-
ATPase was enhanced by aldosterone while in the MCT,
Na-K-ATPase was driven by hypokalemia. In this study, the
animals which received vanadate had a normal plasma bicar-
bonate concentration. We previously showed that chronic
vanadate administration causes hypokalemic distal renal tubu-
lar acidosis when given in this dose to rats [18]. The difference
between the present study and the previous one is the admin-
istration of furosemide. As shown in this study, furosemide
alone stimulates H-ATPase activity in the MCT. It is possible
that this stimulation counteracted the inhibitory effect of vana-
date on H-K-ATPase, resulting in "normal" whole kidney
acidification. A direct study of urinary acidification is necessary
to confirm this suspicion.
Patients with Bartter's syndrome have hypokalemic meta-
bolic alkalosis [28]. It is likely that Bartter's syndrome results
from impaired thick ascending limb transport and, therefore,
resembles chronic furosemide administration [29]. Our data
show that hypokalemia develops in adrenalectomized rats with
physiologic aldosterone replacement in association with an
increase in fractional potassium excretion. This observation
suggests that potassium wastage is due, in part, to impaired
potassium absorption in the ascending limb. Increased potas-
sium excretion was seen even after Na-K-ATPase inhibition, a
maneuver which should reduce cortical collecting tubule potas-
sium secretion.
We suggest the following hypothesis about Bartter's syn-
drome. Impaired ascending limb transport causes sodium chlo-
ride and potassium loss. The salt loss stimulates aldosterone
release. Aldosterone stimulates the H-ATPase enzyme in both
CCT and MCT while stimulating the Na-K-ATPase enzyme in
CCT. This effect on Na-K-ATPase further stimulates the potas-
sium wastage. Hypokalemia stimulates H-K-ATPase activity in
both nephron sites and enhances Na-K-ATPase activity in the
MCT. If luminal Na-K-ATPase exists, as proposed by Hayashi
and Katz [15], the stimulation of the Na-K-ATPase enzyme
would mitigate the potassium losing effect, but acidification
would be markedly stimulated. The result would be hypokale-
mic metabolic alkalosis. The persistence of hypokalemia in
patients with Bartter's syndrome following adrenalectomy sug-
gests that decreased thick ascending limb reabsorption is the
etiology [30, 31].
In summary, our data are in agreement with an increasing
number of reports which suggest that terminal nephron acidifi-
cation is mediated by two proton ATPases, an H-ATPase and
an H-K-ATPase. The former appears to be regulated by aldo-
sterone while the latter responds inversely to plasma potassium
concentration. Cortical collecting tubule potassium transport
appears mediated by both the Na-K-ATPase and the H-K-
ATPase.
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